To determine how ATM mutations enhance the immunogenicity of bladder cancer and activate antitumor immunity, we compared the expression differences in 74 immune-related genes (antigen presentation/stimulation/inhibition) and immune cell-related genes between the ATM-MT group and AMT-WT group. The gene discussed is ATM; the disease is urinary bladder cancer.